Biocytogen Pharmaceuticals Expects Upto 444% Higher Profit in 2025

MT Newswires Live
01/29

Biocytogen Pharmaceuticals (Beijing) (HKG:2315) said it expects to book up to 444% higher profit in 2025, according to a Hong Kong bourse filing Thursday.

The firm expects 162.4 million yuan to 182.4 million yuan in attributable profit for the year, 384% to 444% higher than the 33.5 million yuan posted in 2024.

Revenue is expected to rise 40% to 42% year on year to 1.34 billion yuan to 1.39 billion yuan.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10